A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear)
| العنوان: | A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear) |
|---|---|
| المؤلفون: | Colin A. Hutchison, Hussain Allawati, Shaiju Thaikandy, Linda Dallas, Janine Palmer, Sreejith Nair |
| المصدر: | Toxins, Vol 12, Iss 317, p 317 (2020) Toxins Volume 12 Issue 5 |
| بيانات النشر: | MDPI AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Metabolic Clearance Rate, Health, Toxicology and Mutagenesis, medicine.medical_treatment, vancomycin, 030232 urology & nephrology, Urology, lcsh:Medicine, Theranova, Toxicology, Article, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Renal Dialysis, high-flux, medicine, Humans, In patient, 030212 general & internal medicine, Renal Insufficiency, Chronic, Dialysis, Aged, Cross-Over Studies, medium cut-off, Maintenance dose, business.industry, Revaclear, lcsh:R, Membranes, Artificial, Equipment Design, Middle Aged, Anti-Bacterial Agents, Molecular Weight, haemodialysis, High flux, Membrane, Vancomycin, Female, Drug Monitoring, Open label, business, Porosity, medicine.drug |
| الوصف: | Medium cut-off membrane (MCO) dialysers have been shown to remove a range of middle molecules, which are associated with adverse outcomes in haemodialysis (HD) patients, more effectively than high-flux HD. Vancomycin is widely used in HD patients for treating a variety of infections. To avoid subtherapeutic trough concentrations, it is important to understand vancomycin clearance in patients undergoing HD with the MCO membrane. This open label single centre, cross-over clinical study compared the vancomycin pharmacokinetics in chronic HD patients using MCO membrane (Theranova) and high-flux membrane (Revaclear). Five patients established on chronic HD who were due to receive vancomycin were enrolled. The study used alternating Theranova and Revaclear dialysis membranes over six consecutive sessions. Vancomycin was administered over the last one to two hours of each HD session. The maintenance dose was adjusted based on pre-HD serum concentrations. Over the 210 study samples, vancomycin clearance was higher with MCO-HD compared to high-flux HD but not statistically significant. Median percentage of vancomycin removal at 120 min by MCO membrane was 39% (20.6&ndash 51.5%) compared with 34.1% (21.3&ndash 48.4%) with high-flux HD. MCO-HD removes a slightly higher percentage of vancomycin at 120 min into dialysis compared to high-flux membrane dialysis in HD patients with infections. Application of vancomycin during the last one to two hours of each dialysis is required to maintain therapeutic concentrations to minimise loss through the dialyser and maintain therapeutic levels. |
| وصف الملف: | application/pdf |
| تدمد: | 2072-6651 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e20d8575ab366848d08c7e61f57fb81dTest https://doi.org/10.3390/toxins12050317Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e20d8575ab366848d08c7e61f57fb81d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726651 |
|---|